This talk will explain how obesity drives heart failure, particularly HFpEF and will outline the recommended management of HFpEF on patients with obesity, that includes using incretin therapy.
LDL-C drives atherosclerosis. This talk reviews the latest evidence, new LDL-C targets for at-risk groups, and current treatment options for managing this major cardiovascular risk factor.
Explore the challenges presented by patient adherence in cardiovascular medicine, and the proven strategies effective in improving adherence rates, including the use of easily-accessible digital tools.
An overview of the evidence and the current recommendations in terms of MHT's role in preventing cardiovascular disease will be discussed as well as its safety in women with pre-existing cardiovascular disease.